問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

List

3138Cases

2011-07-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2010-09-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2012-12-13 - 2016-10-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2013-06-01 - 2014-12-31

Phase III

A phase III randomised, double-blind and placebo-controlled study of BI 207127 NA in combination with faldaprevir and ribavirin for chronic genotype 1b hepatitis C virus infection in an extended population of treatment naïve patients that includes those ineligible to receive peginterferon

  • Condition/Disease

    Hepatitis C virus

  • Test Drug

    BI 207127 , Faldaprevir (BI 201335 NA)

Participate Sites
10Sites

Terminated10Sites

2010-02-01 - 2011-01-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Terminated13Sites

2012-09-14 - 2016-12-31

Phase III

A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 for 12 or 24 weeks in combination with pegylated interferon-α and ribavirin in treatment-naïve and prior relapser patients with genotype 1 chronic hepatitis C infection.

  • Condition/Disease

    Hepatitis C virus

  • Test Drug

    BI 201335

Participate Sites
9Sites

Terminated9Sites

2012-12-03 - 2015-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2012-01-01 - 2013-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2011-07-01 - 2013-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2009-12-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

1 302 303 304 305 306 314
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB